Evidence map›Paper›PMID 38731812›Full record

ArticleInternational journal of molecular sciences2024

Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms.

Farida Dakterzada, Raffaela Cipriani, Ricard López-Ortega, Alfonso Arias, Iolanda Riba-Llena, Maria Ruiz-Julián, Raquel Huerto, Nuria Tahan, Carlos Matute, Estibaliz Capetillo-Zarate and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Farida DakterzadaCognitive Disorders Unit, Cognition and Behaviour Study Group, Santa Maria University Hospital, IRBLleida, 25198 Lleida, Spain.ORCID 0000-0001-9720-7160
Raffaela CiprianiAchucarro Basque Center for Neuroscience, 48940 Leioa, Spain.
Ricard López-OrtegaLaboratori ClínicInstitut Català de la Salut (ICS), Hospital Universitari Arnau de Vilanova, 25198 Lleida, Spain.ORCID 0000-0002-4604-7862
Alfonso AriasCognitive Disorders Unit, Cognition and Behaviour Study Group, Santa Maria University Hospital, IRBLleida, 25198 Lleida, Spain.
Iolanda Riba-LlenaCognitive Disorders Unit, Cognition and Behaviour Study Group, Santa Maria University Hospital, IRBLleida, 25198 Lleida, Spain.
Maria Ruiz-JuliánCognitive Disorders Unit, Cognition and Behaviour Study Group, Santa Maria University Hospital, IRBLleida, 25198 Lleida, Spain.
Raquel HuertoCognitive Disorders Unit, Cognition and Behaviour Study Group, Santa Maria University Hospital, IRBLleida, 25198 Lleida, Spain.
Nuria TahanCognitive Disorders Unit, Cognition and Behaviour Study Group, Santa Maria University Hospital, IRBLleida, 25198 Lleida, Spain.
Carlos MatuteAchucarro Basque Center for Neuroscience, 48940 Leioa, Spain.ORCID 0000-0001-8672-711X
Estibaliz Capetillo-ZarateAchucarro Basque Center for Neuroscience, 48940 Leioa, Spain.ORCID 0000-0002-8416-0495
Gerard Piñol-RipollCognitive Disorders Unit, Cognition and Behaviour Study Group, Santa Maria University Hospital, IRBLleida, 25198 Lleida, Spain.

Funding

Diputació de Lleida PP10605 - PIRS2021Fundación Vasca de Innovación e Investigación Sanitarias #BIO22/ALZ/014 and #BIO22/ALZ/015Instituto de salud carlos III PI22/01687IRBLleida IREP-2023 postdoctoral fellowship
6 · The paper itself

Abstract

We compared the clinical and analytical performance of Alzheimer's disease (AD) plasma biomarkers measured using the single-molecule array (Simoa) and Lumipulse platforms. We quantified the plasma levels of amyloid beta 42 (Aβ42), Aβ40, phosphorylated tau (Ptau181), and total tau biomarkers in 81 patients with mild cognitive impairment (MCI), 30 with AD, and 16 with non-AD dementia. We found a strong correlation between the Simoa and Lumipulse methods. Concerning the clinical diagnosis, Simoa Ptau181/Aβ42 (AUC 0.739, 95% CI 0.592-0.887) and Lumipulse Aβ42 and Ptau181/Aβ42 (AUC 0.735, 95% CI 0.589-0.882 and AUC 0.733, 95% CI 0.567-0.900) had the highest discriminating power. However, their power was significantly lower than that of CSF Aβ42/Aβ40, as measured by Lumipulse (AUC 0.879, 95% CI 0.766-0.992). Simoa Ptau181 and Lumipulse Ptau181/Aβ42 were the markers most consistent with the CSF Aβ42/Aβ40 status (AUC 0.801, 95% CI 0.712-0.890 vs. AUC 0.870, 95% CI 0.806-0.934, respectively) at the ≥2.127 and ≥0.084 cut-offs, respectively. The performance of the Simoa and Lumipulse plasma AD assays is weaker than that of CSF AD biomarkers. At present, the analysed AD plasma biomarkers may be useful for screening to reduce the number of lumbar punctures in the clinical setting.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitive Dysfunctiontau ProteinsAgedAged, 80 and overFemaleHumansMaleMiddle AgedPeptide FragmentsPhosphorylationAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersPeptide Fragmentstau ProteinsAlzheimer’s diseasebiomarkercerebrospinal fluidcut-offLumipulseplasmaSimoa

Identifiers

PMID38731812
PMCPMC11083365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.